{"id":1855,"date":"2001-06-01T12:09:00","date_gmt":"2001-06-01T10:09:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/betarezeptoren-blocker-bei-schwerer-herzinsuffizienz-die-copernicus-und-die-best-studie"},"modified":"2001-06-01T12:09:00","modified_gmt":"2001-06-01T10:09:00","slug":"betarezeptoren-blocker-bei-schwerer-herzinsuffizienz-die-copernicus-und-die-best-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/betarezeptoren-blocker-bei-schwerer-herzinsuffizienz-die-copernicus-und-die-best-studie","title":{"rendered":"Betarezeptoren-Blocker bei schwerer Herzinsuffizienz. Die COPERNICUS- und die BEST-Studie"},"content":{"rendered":"<p>Als Ende der achtziger Jahre die ersten Berichte \u00fcber g\u00fcnstige Wirkungen der Beta-Blocker bei Herzinsuffizienz kamen, war die Redaktion des ARZNEIMITTELBRIEFS skeptisch (1). Nach der CIBIS-Studie (Bisoprolol; 2), der MDC-Studie (Metoprolol; 3), der MERIT-HF-Studie (Metoprolol; 4) und den Untersuchungen zu Carvedilol (5) hat sich das Blatt aber gewendet. Beta-Blocker geh\u00f6ren heute bei Patienten mit stabiler [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Als Ende der achtziger Jahre die ersten Berichte \u00fcber g\u00fcnstige Wirkungen der Beta-Blocker bei Herzinsuffizienz kamen, war die Redaktion des ARZNEIMITTELBRIEFS skeptisch (1). Nach der CIBIS-Studie (Bisoprolol; 2), der MDC-Studie (Metoprolol; 3), der MERIT-HF-Studie (Metoprolol; 4) und den Untersuchungen zu Carvedilol (5) hat sich das Blatt aber gewendet. Beta-Blocker geh\u00f6ren heute bei Patienten mit stabiler [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2525,129,128,131,2524,1639,2526,180],"class_list":["post-1855","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-best-studie","tag-beta-blocker","tag-betablocker","tag-betarezeptoren-blocker","tag-bucindolol","tag-carvedilol","tag-copernicus-studie","tag-herzinsuffizienz"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1855"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1855\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1855"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1855"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}